Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study.

Kristof RA, Stoffel-Wagner B, Klingmüller D, Schramm J

Acta neurochirurgica1 Jan 1999Cited by 59 (Europe PMC)

PMID10352750DOI10.1007/s007010050316PepBankPUB-10352750

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In acromegaly, postoperative remission was 55% after octreotide pretreatment versus 69% without pretreatment, without a significant difference.
In plain wordsIn acromegaly, remission was 55% after octreotide pretreatment versus 69% without pretreatment, without a significant difference.
Peptide
Octreotide
Outcome
DecreasePostoperative remission
Study
n = 24
Comparator
No preoperative octreotide
Outcome group
Disease Remission · Endocrine and hormones
Studied dose
470 +/- 160 micrograms daily · 16.5 +/- 10 weeksAs given in this study (human).
Measurements
Postoperative acromegaly remission rate
55%
group A, preoperative octreotide
Postoperative acromegaly remission rate
69%
group B, no preoperative octreotide
Source sentences
Summary
There was no statistically significant difference between the postoperative acromegaly remission rates of 55% in group A and 69% in group B.
2 context sentences(design, population, supporting numbers)
Title · context
Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study.
Summary · context
In a prospective controlled study the results of transsphenoidal surgery in newly diagnosed GH-secreting macro-adenomas were compared in patients with (n = 11, group A) and without (n = 13, group B) preoperative Octreotide treatment.
Report a problemFND-1035275004
02HumanRandomized controlled trialEfficacy outcome
In acromegaly, postoperative anterior pituitary function did not differ significantly with versus without octreotide pretreatment.
In plain wordsIn acromegaly, postoperative pituitary function did not differ significantly with versus without octreotide pretreatment.
Peptide
Octreotide
Outcome
No significant changePostoperative anterior pituitary function
Study
n = 24
Comparator
No preoperative octreotide
Outcome group
Pituitary Function · Endocrine and hormones
Studied dose
470 +/- 160 micrograms daily · 16.5 +/- 10 weeksAs given in this study (human).
Source sentences
Summary
There was no statistically significant difference between the postoperative anterior pituitary function in the two patient groups.
2 context sentences(design, population, supporting numbers)
Title · context
Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study.
Summary · context
In a prospective controlled study the results of transsphenoidal surgery in newly diagnosed GH-secreting macro-adenomas were compared in patients with (n = 11, group A) and without (n = 13, group B) preoperative Octreotide treatment.
Report a problemFND-1035275006
03HumanNon-randomized trialEfficacy outcome
In acromegaly, octreotide reduced GH from 38.9 +/- 34.1 to 6.8 +/- 4.9 micrograms/l significantly.
In plain wordsIn acromegaly, GH declined significantly during octreotide treatment compared with pretreatment.
Peptide
Octreotide
Outcome
DecreaseGH concentration
Study
n = 11
Comparator
Pretreatment
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
470 +/- 160 micrograms daily · 16.5 +/- 10 weeksAs given in this study (human).
Measurements
GH concentration
38.9 micrograms/l
group A before octreotide (SD 34.1)
GH concentration
6.8 micrograms/l
group A during octreotide (SD 4.9)
Source sentences
Summary
During the treatment with a daily dosage of 470 +/- 160 micrograms Octreotide for 16.5 +/- 10 weeks, the GH- and IGF-1-values of group A dropped significantly from 38.9 +/- 34.1 to 6.8 +/- 4.9 micrograms/l and from 2.7 +/- 1 to 1.7 +/- 0.7 arbitrary units respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
In a prospective controlled study the results of transsphenoidal surgery in newly diagnosed GH-secreting macro-adenomas were compared in patients with (n = 11, group A) and without (n = 13, group B) preoperative Octreotide treatment.
Report a problemFND-1035275001
04HumanNon-randomized trialEfficacy outcome
In acromegaly, octreotide reduced IGF-1 from 2.7 +/- 1 to 1.7 +/- 0.7 arbitrary units significantly.
In plain wordsIn acromegaly, IGF-1 declined significantly during octreotide treatment compared with pretreatment.
Peptide
Octreotide
Outcome
DecreaseIGF-1 concentration
Study
n = 11
Comparator
Pretreatment
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
470 +/- 160 micrograms daily · 16.5 +/- 10 weeksAs given in this study (human).
Measurements
IGF-1 concentration
2.7 arbitrary units
group A before octreotide (SD 1)
IGF-1 concentration
1.7 arbitrary units
group A during octreotide (SD 0.7)
Source sentences
Summary
During the treatment with a daily dosage of 470 +/- 160 micrograms Octreotide for 16.5 +/- 10 weeks, the GH- and IGF-1-values of group A dropped significantly from 38.9 +/- 34.1 to 6.8 +/- 4.9 micrograms/l and from 2.7 +/- 1 to 1.7 +/- 0.7 arbitrary units respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
In a prospective controlled study the results of transsphenoidal surgery in newly diagnosed GH-secreting macro-adenomas were compared in patients with (n = 11, group A) and without (n = 13, group B) preoperative Octreotide treatment.
Report a problemFND-1035275002
05HumanNon-randomized trialEfficacy outcome
In acromegaly, adenoma volume fell from 5.9 +/- 5.8 to 4.7 +/- 4.9 cm3 during octreotide treatment, and the change missed statistical significance by little.
In plain wordsIn acromegaly, adenoma volume declined during octreotide treatment compared with pretreatment, and the change narrowly missed statistical significance.
Peptide
Octreotide
Outcome
DecreaseAdenoma volume
Study
n = 11
Comparator
Pretreatment
Outcome group
Tumor growth · Endocrine and hormones
Studied dose
470 +/- 160 micrograms daily · 16.5 +/- 10 weeksAs given in this study (human).
Measurements
Adenoma volume
5.9 cm3
group A before octreotide (SD 5.8)
Adenoma volume
4.7 cm3
group A during octreotide (SD 4.9)
Source sentences
Summary
The adenoma-shrinkage from 5.9 +/- 5.8 to 4.7 +/- 4.9 cm3 missed statistical significance by little.
1 context sentence(design, population, supporting numbers)
Summary · context
In a prospective controlled study the results of transsphenoidal surgery in newly diagnosed GH-secreting macro-adenomas were compared in patients with (n = 11, group A) and without (n = 13, group B) preoperative Octreotide treatment.
Report a problemFND-1035275003
06HumanObservational studyEfficacy outcome
Among nonremitting acromegaly adenomas, infiltrative growth occurred in 80% after octreotide versus 75% without pretreatment, reportedly unaffected by pretreatment.
In plain wordsAmong nonremitting acromegaly tumors, infiltrative growth occurred in 80% after octreotide versus 75% without pretreatment.
Peptide
Octreotide
Outcome
IncreaseInfiltrative growth among nonremitting adenomas
Study
n: not reported in source
Comparator
No preoperative octreotide
Outcome group
Tumor growth · Endocrine and hormones
Studied dose
470 +/- 160 micrograms daily · 16.5 +/- 10 weeksAs given in this study (human).
Measurements
Infiltrative growth pattern among non-remission adenomas
80%
group A, preoperative octreotide
Infiltrative growth pattern among non-remission adenomas
75%
group B, no preoperative octreotide
Source sentences
Summary
Of the adenomas that postoperatively were not in remission, 80% in group A and 75% in group B disclosed an infiltrative growth pattern not influenced by the Octreotide pretreatment.
2 context sentences(design, population, supporting numbers)
Title · context
Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study.
Summary · context
In a prospective controlled study the results of transsphenoidal surgery in newly diagnosed GH-secreting macro-adenomas were compared in patients with (n = 11, group A) and without (n = 13, group B) preoperative Octreotide treatment.
Report a problemFND-1035275005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.